STOCK TITAN

Cellectar Biosciences Inc - CLRB STOCK NEWS

Welcome to our dedicated page for Cellectar Biosciences news (Ticker: CLRB), a resource for investors and traders seeking the latest updates and insights on Cellectar Biosciences stock.

About Cellectar Biosciences Inc.

Cellectar Biosciences Inc. (NASDAQ: CLRB) is a late-stage clinical biopharmaceutical company dedicated to advancing the treatment of cancer through its proprietary Phospholipid Drug Conjugate™ (PDC) platform. This innovative technology is designed to deliver therapeutic payloads directly to cancer cells, offering enhanced efficacy and reduced off-target effects. By leveraging its PDC platform, the company aims to address significant unmet medical needs in oncology while improving patient outcomes.

Core Technology: The PDC Platform

Cellectar’s PDC platform is based on proprietary phospholipid ether analogs, which demonstrate highly selective uptake and retention in cancer cells. This precision-targeting capability enables the development of therapies that minimize damage to healthy tissue, making it a promising approach for both therapeutic and diagnostic applications. The platform supports the delivery of various oncologic payloads, including radioisotopes, chemotherapeutics, and other therapeutic agents.

Pipeline and Lead Product Candidates

The company’s product pipeline includes a diverse range of assets designed to target hematologic malignancies and solid tumors:

  • Iopofosine I 131: A small-molecule PDC utilizing iodine-131, a cytotoxic radioisotope, to target and destroy cancer cells. This lead asset is under evaluation in clinical trials for multiple indications, including Waldenstrom’s macroglobulinemia (WM), multiple myeloma, and central nervous system lymphoma. It has received Orphan Drug and Fast Track Designations from the U.S. FDA for various cancer indications.
  • CLR 121225: An actinium-225-based alpha-emitting radioconjugate targeting solid tumors such as pancreatic and triple-negative breast cancers. This program aims to leverage the precision of alpha emitters for enhanced efficacy in difficult-to-treat cancers.
  • CLR 121125: An iodine-125 Auger-emitting radioconjugate with applications in triple-negative breast, lung, and colorectal cancers. Auger emitters offer unparalleled precision, delivering therapeutic effects at the subcellular level.

Strategic Focus and Market Position

Cellectar’s strategy combines internal drug development with external collaborations to maximize the potential of its PDC platform. By partnering with other biopharmaceutical companies, Cellectar expands the applicability of its technology while diversifying its revenue streams. The company’s focus on radiopharmaceuticals positions it within a niche but growing segment of the oncology market, where demand for targeted therapies is increasing.

Industry Challenges and Opportunities

Operating in the competitive oncology sector, Cellectar faces challenges such as regulatory approvals, supply chain complexities for rare isotopes, and significant capital requirements for clinical development. However, its proprietary platform, coupled with a robust pipeline and strategic collaborations, provides a strong foundation for addressing these challenges. The company’s focus on unmet medical needs and orphan drug markets further enhances its growth potential.

Commitment to Innovation

With a mission to revolutionize cancer treatment, Cellectar continues to advance its pipeline and explore new applications for its PDC platform. Its dedication to innovation, combined with a strategic approach to development and commercialization, underscores its potential to make a lasting impact in oncology.

Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB), a clinical biopharmaceutical company, will host a key opinion leader event on July 24, 2024, at 8:00 a.m. EDT. This event will cover the latest data from the CLOVER WaM pivotal trial of iopofosine I 131 for Waldenstrom’s macroglobulinemia. The company aims to offer a comprehensive review of the trial's results, current treatment landscape, unmet patient needs, and potential improvements in patient outcomes. The event will feature insights from both company leaders and key study investigators. A replay of the conference call will be available on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.38%
Tags
conferences
-
Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) has formed a strategic partnership with City of Hope Cancer Center to evaluate the efficacy of its lead drug, iopofosine I 131, in treating mycosis fungoides (MF), a rare form of non-Hodgkin's lymphoma (NHL). This collaboration aims to initiate trials with around 10 patients by late 2024 or early 2025. Iopofosine I 131, the first systemic targeted radiotherapeutic for cutaneous T-cell lymphomas (CTCL), may provide advantages over conventional treatments by targeting tumor cells beyond the skin. Cellectar is set to submit a New Drug Application (NDA) to the FDA in late 2024 based on its CLOVER WaM pivotal study results in Waldenstrom's macroglobulinemia (WM).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
none
-
Rhea-AI Summary

Cellectar Biosciences (NASDAQ: CLRB) reported its Q1 2024 financial results and shared a corporate update. Key highlights include positive topline data from the CLOVER WaM pivotal study for iopofosine I 131 in Waldenstrom’s macroglobulinemia, which met its primary endpoint with a major response rate of 61% and an overall response rate of 75.6%. Further data for all evaluable patients will be announced in June 2024. The company also reported a complete remission rate of 64% in a Phase I study of iopofosine in recurrent head and neck cancer. Financially, the company had $40 million in cash as of March 31, 2024, with a net loss of $21.6 million for the quarter. R&D expenses increased to $7.4 million, while G&A expenses rose to $4.6 million, contributing to the loss.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
Rhea-AI Summary

Cellectar Biosciences, Inc. (NASDAQ: CLRB) will present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day in New York City on May 13, 2024. Jarrod Longcor, the company's COO, will provide an overview of Cellectar in a fireside chat.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.74%
Tags
conferences
-
Rhea-AI Summary

Cellectar Biosciences, Inc. (NASDAQ: CLRB) will announce its first-quarter financial results on May 14, 2024. The company focuses on developing cancer treatments and will host a conference call to discuss the results and provide an overview at 8:30 am Eastern Time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
-
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) announced positive financial results for 2023 and provided a corporate update, highlighting significant progress in its pivotal study of iopofosine I 131 in Waldenstrom’s macroglobulinemia. The company reported a major response rate of 61% in relapsed/refractory patients, with durable responses and high rates of disease control. Additionally, Cellectar achieved a complete remission rate of 64% in head and neck cancer patients and demonstrated complete clonal clearance in a patient with Bing-Neel Syndrome. The company also initiated a Phase 1b study in pediatric high-grade gliomas and presented promising preclinical data for CLR 121255 in pancreatic cancer models. Cellectar expanded its IP protection and successfully exercised Tranche A warrants, raising approximately $44.1 million. Financially, the company had $9.6 million in cash and cash equivalents as of December 31, 2023, with a net loss of ($38.0) million for the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) will release its financial results for the year ended December 31, 2023, on March 27, 2024. The company, specializing in cancer treatment drugs, will host a conference call at 8:30 am Eastern Time to discuss the results with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) announces Jim Caruso, the President and CEO, will present at the 36th Annual Roth Conference. The presentation will focus on the company's overview and future prospects in cancer drug development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
conferences
-
Rhea-AI Summary
Cellectar Biosciences, Inc. (CLRB) announces positive results from a Phase 1 clinical trial showcasing a 64% complete remission rate and a 73% overall response rate in highly refractory patients with head and neck squamous cell carcinoma. The study also highlights a 67% overall survival and a 42% progression-free survival at one year. The combination of iopofosine I 131 with external beam radiation therapy was well-tolerated, showing promising therapeutic effects without significant toxicity increase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.95%
Tags
Rhea-AI Summary
Cellectar Biosciences, Inc. (NASDAQ: CLRB) announced that James Caruso, president and CEO, will present an overview of the company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The presentation will be held virtually on February 14, 2024, at 2:00 – 2:30 pm Eastern Time. A webcast will be available, and a replay can be accessed on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences

FAQ

What is the current stock price of Cellectar Biosciences (CLRB)?

The current stock price of Cellectar Biosciences (CLRB) is $0.292 as of April 1, 2025.

What is the market cap of Cellectar Biosciences (CLRB)?

The market cap of Cellectar Biosciences (CLRB) is approximately 13.6M.

What is Cellectar Biosciences' core technology?

Cellectar Biosciences utilizes its proprietary Phospholipid Drug Conjugate (PDC) platform to deliver therapeutic payloads directly to cancer cells, enhancing efficacy and minimizing off-target effects.

What is iopofosine I 131?

Iopofosine I 131 is Cellectar's lead asset, a small-molecule PDC that uses iodine-131 to target and destroy cancer cells. It is under clinical evaluation for multiple cancer indications.

What types of cancers does Cellectar target?

Cellectar focuses on both hematologic malignancies, such as multiple myeloma and Waldenstrom’s macroglobulinemia, and solid tumors, including pancreatic, triple-negative breast, and colorectal cancers.

How does Cellectar differentiate itself from competitors?

Cellectar’s proprietary PDC platform enables precise targeting of cancer cells, reducing off-target effects and improving safety. Its focus on radiopharmaceuticals and orphan drug markets further differentiates it.

What are the key challenges Cellectar faces?

Cellectar faces challenges such as regulatory hurdles, isotope supply chain complexities, and the high capital requirements typical of clinical-stage biopharmaceutical companies.

What is CLR 121225?

CLR 121225 is an actinium-225-based radioconjugate targeting solid tumors. It leverages alpha-emitting isotopes for precision therapy in cancers with significant unmet needs.

What is the significance of the PDC platform?

The PDC platform enables targeted delivery of diverse therapeutic payloads to cancer cells, improving efficacy and safety. It supports both internal drug development and external collaborations.

What regulatory designations has Cellectar received?

Cellectar’s lead asset, iopofosine I 131, has received Orphan Drug and Fast Track Designations from the U.S. FDA for various indications, highlighting its potential in addressing unmet medical needs.
Cellectar Biosciences Inc

Nasdaq:CLRB

CLRB Rankings

CLRB Stock Data

13.61M
45.32M
1.64%
11%
4.27%
Biotechnology
Pharmaceutical Preparations
Link
United States
FLORHAM PARK